JSH-23: Small Molecule NF-κB Inhibitor for Inflammation Research

Executive Summary: JSH-23 (CAS 749886-87-1) is a selective small molecule inhibitor of NF-κB transcriptional activity with an IC50 of 7.1 μM in cell-based assays, acting by preventing p65 nuclear translocation and DNA binding without affecting IκB degradation (APExBIO). It reduces expression of pro-inflammatory mediators including IL-6, IL-1β, COX-2, and TNF-α in LPS-stimulated RAW 264.7 macrophages (see preprint). In cisplatin-induced acute kidney injury mouse models, JSH-23 administration lowers BUN, serum creatinine, and tubular necrosis scores. JSH-23 is supplied as a solid (C16H20N2, MW 240.34), soluble in DMSO (≥24 mg/mL) and ethanol (≥17.1 mg/mL, with ultrasonication), but insoluble in water. Proper storage at -20°C is recommended for stability (APExBIO).

Biological Rationale

NF-κB is a transcription factor complex central to inflammation, immunity, and cell survival. Aberrant NF-κB activation is implicated in chronic inflammatory diseases, autoimmune conditions, and cancer. The p65 (RelA) subunit is critical for NF-κB's transcriptional activation of pro-inflammatory genes. Small molecule inhibitors such as JSH-23 enable precise modulation of NF-κB signaling, supporting both mechanistic studies and translational applications in inflammation models (JSH-23: Advanced Insights). This article extends prior summaries by providing atomic, verifiable claims and rigorous parameterization for research use.

Mechanism of Action of JSH-23

JSH-23 selectively inhibits NF-κB-driven gene transcription by blocking nuclear translocation and DNA binding of the p65 subunit. It does not interfere with upstream IκB degradation, distinguishing it from proteasome or IKK inhibitors (APExBIO). In LPS-stimulated murine RAW 264.7 macrophages, JSH-23 prevents p65 from localizing to the nucleus, resulting in reduced transcription of target cytokines and inflammatory enzymes. The compound's selectivity for p65 nuclear translocation is critical for dissecting downstream effects in NF-κB pathway studies (Unveiling Mechanistic Precision).

Evidence & Benchmarks

• JSH-23 inhibits NF-κB transcriptional activity with an IC50 of 7.1 μM in cell-based reporter assays (APExBIO).
• It blocks nuclear translocation and DNA binding of the NF-κB p65 subunit without affecting IκB degradation, as measured by immunofluorescence and western blotting (APExBIO).
• In LPS-stimulated RAW 264.7 macrophages, JSH-23 significantly reduces mRNA and protein levels of IL-6, IL-1β, COX-2, and TNF-α (Gao et al., 2023 preprint).
• JSH-23 decreases apoptotic chromatin condensation in activated macrophages, as assessed by DAPI staining (APExBIO).
• In cisplatin-induced acute kidney injury (AKI) models in male C57BL/6 mice, intraperitoneal JSH-23 administration reduces blood urea nitrogen (BUN), serum creatinine, serum neutrophil gelatinase-associated lipocalin (NGAL), IL-1, IL-6, CXCL1, and TNF-α, and decreases acute tubular necrosis scores and MPO activity (APExBIO).

These results clarify and extend the mechanistic benchmarks discussed in JSH-23: A Transformative Tool, focusing on direct evidence and quantitative endpoints.

Applications, Limits & Misconceptions

JSH-23 is primarily utilized in basic and translational research to dissect the NF-κB signaling pathway, inflammation, and related cellular processes. Key applications include:

• Inhibition of NF-κB-dependent cytokine and chemokine expression in cell culture and animal models.
• Acute and chronic inflammation models, including LPS-induced macrophage activation and cisplatin-induced AKI.
• Probing the role of NF-κB in apoptosis and cell survival.
• Studying pathway crosstalk, e.g., NLRP3 inflammasome regulation via NF-κB (Gao et al., 2023 preprint).

This article updates prior coverage in Advanced Strategies for Targeting NF-κB in Inflammation by highlighting new quantitative parameters and validated use cases for JSH-23.

Common Pitfalls or Misconceptions

• JSH-23 does not block IκB degradation—upstream signaling remains intact.
• It is not suitable for use in water-based buffers due to insolubility; use DMSO or ethanol with ultrasonic assistance.
• Long-term storage of solutions is not recommended; prepare fresh aliquots before use.
• JSH-23 specificity is limited to NF-κB p65 nuclear translocation—other pathways may remain unaffected.
• In vivo efficacy and dosing must be carefully titrated; preclinical results may not directly translate to clinical outcomes.

Workflow Integration & Parameters

• Formulation: Solid, MW 240.34, chemical formula C₁₆H₂₀N₂.
• Solubility: ≥24 mg/mL in DMSO; ≥17.1 mg/mL in ethanol (ultrasonication); insoluble in water.
• Storage: -20°C; avoid long-term solution storage.
• Cell-based assays: Typical working concentration 5–20 μM; titrate as needed for cell line and endpoint.
• Animal dosing: Intraperitoneal injection in preclinical models; dosing regimens (e.g., 5–25 mg/kg) depend on model and endpoint (APExBIO).
• Controls: Include vehicle and positive controls for accurate interpretation.

For further technical details, consult the JSH-23 product page (B1645) from APExBIO.

Conclusion & Outlook

JSH-23 is a rigorously validated small molecule inhibitor of NF-κB transcriptional activity. Its mechanism—blocking p65 nuclear translocation—enables precise interrogation of inflammatory gene regulation in vitro and in vivo. Key quantitative benchmarks and handling parameters are now well established. As research continues to elucidate the NF-κB axis in disease, JSH-23 will remain a critical tool, especially when integrated with complementary models of inflammasome biology and cytokine inhibition. For updated applications and detailed mechanistic discussion, see the related article JSH-23 and the Future of NF-κB Pathway Modulation, which this summary extends with atomic level evidence and workflow parameters.